{"result": "(\"entity\"<|>HIPÓFISIS<|>ORGANIZATION<|>The hypophysis, or pituitary gland, is a crucial endocrine gland that regulates various hormonal functions in the body, including the secretion of prolactin.)\n##\n(\"entity\"<|>HIPERPROLACTINEMIA<|>EVENT<|>Hiperprolactinemia is a medical condition characterized by elevated levels of prolactin in the blood, which can lead to various physiological and pathological effects.)\n##\n(\"entity\"<|>ADENOMAS HIPOFISARIOS<|>ORGANIZATION<|>Adenomas hipofisarios are benign tumors of the pituitary gland that can produce excess prolactin, leading to conditions such as hyperprolactinemia.)\n##\n(\"entity\"<|>TRH<|>ORGANIZATION<|>Thyrotropin-releasing hormone (TRH) is a hormone that stimulates the release of prolactin from the pituitary gland and is involved in the regulation of thyroid function.)\n##\n(\"entity\"<|>GNRH<|>ORGANIZATION<|>Gonadotropin-releasing hormone (GnRH) is a hormone responsible for the release of gonadotropins from the pituitary gland, playing a key role in reproductive health.)\n##\n(\"entity\"<|>FARMACOS<|>ORGANIZATION<|>Various medications can trigger hyperprolactinemia by affecting central aminergic pathways, making them a common cause of elevated prolactin levels in clinical practice.)\n##\n(\"entity\"<|>MACROADENOMA<|>ORGANIZATION<|>Macroadenomas are larger pituitary tumors that can lead to hyperprolactinemia and are more prevalent in women than in men.)\n##\n(\"relationship\"<|>HIPÓFISIS<|>HIPERPROLACTINEMIA<|>The hypophysis is responsible for the secretion of prolactin, and its dysfunction can lead to hyperprolactinemia.<|>8)\n##\n(\"relationship\"<|>ADENOMAS HIPOFISARIOS<|>HIPERPROLACTINEMIA<|>Adenomas hipofisarios are a common pathological cause of hyperprolactinemia due to their ability to produce excess prolactin.<|>7)\n##\n(\"relationship\"<|>TRH<|>HIPÓFISIS<|>TRH stimulates the hypophysis to release prolactin, linking it directly to the regulation of hyperprolactinemia.<|>6)\n##\n(\"relationship\"<|>GNRH<|>HIPÓFISIS<|>GnRH is regulated by the hypophysis and is affected by hyperprolactinemia, indicating a relationship between these entities.<|>5)\n##\n(\"relationship\"<|>FARMACOS<|>HIPERPROLACTINEMIA<|>Certain medications are a frequent cause of hyperprolactinemia, indicating a direct relationship between drug use and elevated prolactin levels.<|>7)\n##\n(\"relationship\"<|>MACROADENOMA<|>HIPERPROLACTINEMIA<|>Macroadenomas are a significant cause of hyperprolactinemia, particularly in women, establishing a clear relationship.<|>6)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: ológicas de hiperprolactinemia\n\n| Mecanismo | Causas |\n|-----------|--------|\n| Aumento de secreción de PRL | • Adenomas hipofisarios productores de prolactina (prolactinomas, acromegalia, tumores plurihormonales)<br>• Producción ectópica de PRL: carcinoma broncogénico o carcinoma de células renales |\n| Reducción de la inhibición dopaminérgica de la PRL | • Tumores: adenomas hipofisarios (no lactotropos), craneofaringiomas, germinomas, meningiomas o metástasis<br>• Enfermedades infiltrativas del hipotálamo (p. ej., tuberculosis, histiocitosis X, sarcoidosis)<br>• Sección del tallo hipofisario (traumática o posquirúrgica, por ejemplo)<br>• Irradiación de la región hipotálamo-hipofisaria<br>• Cirrosis hepática alcohólica y no alcohólica |\n| Disminución del aclaramiento de PRL | • Enfermedad renal crónica<br>• Macroprolactinemia |\n| Mecanismo neural | • Daño en la pared torácica (quemaduras, herpes zóster, traumatismos o cirugía) |\n| Genéticas | • Mutaciones germinales de pérdida de función en el gen del receptor de PRL (asocian hiperprolactinemia con insensibilidad a la PRL en algunos tejidos, pero síntomas derivados de exceso de PRL en otros tejidos que pueden mantener receptores funcionantes de PRL) |\n| Alteraciones endocrinológicas | • Hipotiroidismo primario<br>• Insuficiencia adrenal<br>• Síndrome de ovario poliquístico |\n| Hiperprolactinemia idiopática | • En torno al 15% (en series antiguas se daban cifras más altas, pero cada vez se reconoce mejor la etiología) |\n\nEl hipotiroidismo primario (y no el hipertiroidismo, como afirma la respuesta A) se puede asociar a hiperprolactinemia y galactorrea. La TRH es un potente factor estimulante de la liberación de PRL. En el hipotiroidismo primario hay un aumento tanto en la síntesis de TRH como en la respuesta de la hipófisis a la TRH, que pueda justificar el aumento de PRL y que se resuelve al corregir el hipotiroidismo.\n\nReferencias:\n• Cone RD, Low MJ, Elmquist JK, Cameron JL. Neuroendocrinología. En: Larsen PR, Kronenberg HM, Melmed S, Polonsky KS, eds. Williams Tratado de Endocrinología. Versión en español de la 10.ª edición de la obra original en inglés. Madrid: Elsevier España; 2004. p. 91-192.\n• Villar-Taibo R, Sifontes-Dubon M, Bernabeu-Moron I, Casanueva FF. Prolactin excess and deficiency: Epidemiology, causes (excluding prolactin-secreting pituitary tumors). En: Tritos NA, Klibansky A. Prolactin disorders. From basic science to clinical management. 1.ª ed. Springer Nature Switzerland AG: Humana press; 2019.\n---\n# HIPÓFISIS 1\n\n## 28 ¿Cuál de las siguientes afirmaciones no es correcta con respecto a la hiperprolactinemia?\n\nA. Produce un hipogonadismo hipogonadotropo.\nB. Los fármacos son una causa muy frecuente de hiperprolactinemia.\nC. El macroadenoma es más prevalente en mujeres que en hombres.\nD. Todas las respuestas son correctas.\n\n### COMENTARIO\n\nLa hiperprolactinemia se divide, desde un punto de vista práctico, en tres grandes grupos:\n\n- Fisiológica: en situaciones como el embarazo o la lactancia, estimulación del pezón, estrés o coito.\n- Farmacológica: asociada a diversos fármacos que actúan sobre las vías aminérgicas centrales (véase comentario de la pregunta 27). Los fármacos son el desencadenante más común de hiperprolactinemia en la práctica clínica (respuesta B).\n- Patológica: dentro de la que destacan por frecuencia los adenomas hipofisarios productores de PRL.\n\nLas principales manifestaciones clínicas de la hiperprolactinemia se deben a la supresión del eje hipotálamo-hipófiso-gonadal, con inhibición de los pulsos de GnRH, descenso de gonadotropinas y disminución de la esteroidogénesis adrenal (hipogonadismo hipogonadotropo) (respuesta A).\n\nCuando la causa de la hiperprolactinemia es un prolactinoma, tenemos que tener en cuenta que existen diferencias epidemiológicas entre hombres y mujeres. La prevalencia general del prolactinoma es mayor en mujeres que en varones entre los 20 y 50 años, pero\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}